Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study
Akihito Kawazoe,Rui-Hua Xu,Pilar García-Alfonso,Maria Passhak,Hao-Wei Teng,Ardaman Shergill,Mahmut Gumus,Camilla Qvortrup,Sebastian Stintzing,Kathryn Towns,Tae Won Kim,Kai Keen Shiu,Juan Cundom,Sumitra Ananda,Andrey Lebedinets,Rong Fu,Rishi Jain,David Adelberg,Volker Heinemann,Takayuki Yoshino,Elena Elez,Juan Cundom,Ezequiel Slutsky,Julieta Grasselli,Luis Fein,Luciana Bella Quero,Warren Joubert,Peter Gibbs,Timothy Price,Matthew Burge,Sumitra Ananda,Muhammad Khattak,Bruce Colwell,Felix Couture,Brandon Meyers,Kathryn Towns,Michael Sawyer,Lucas Sideris,Ruihua Xu,Wei Wang,Hongming Pan,Per Pfeiffer,Lars Henrik Jensen,Camilla Qvortrup,Sebastian Stintzing,Dirk Arnold,Sylvie Lorenzen,Stefan Kubicka,Reinhard Depenbusch,Maria Passhak,Ravit Geva,Ayala Hubert,Einat Shacham-Shmueli,Gleb Kornev,Akihito Kawazoe,Toshiki Masuishi,Atsuo Takashima,Hiroki Hara,Hisato Kawakami,Nozomu Machida,Kentaro Yamazaki,Hisateru Yasui,Akihito Tsuji,Taito Esaki,Kensei Yamaguchi,Tae-You Kim,Joong Bae Ahn,Myung Ah Lee,Tae Won Kim,Joon Oh Park,Soohyeon Lee,Rashida Orlova,Vladislav Sarzhevskiy,Marina Sekacheva,Sergey Tjulandin,Oksana Shirokova,Alsu Iskhakova,Andrey Lebedinets,Paula Jimenez Fonseca,Fernando Rivera Herrero,Elena Elez Fernandez,Pilar Garcia Alfonso,Maria Jose Gomez Reina,Kun-Huei Yeh,Hao-Wei Teng,Tsai Sheng Yang,Hwei-Ming Wang,Yu-Min Yeh,Mustafa Ozguroglu,Mahmut Gumus,Suayib Yalcin,Bulent Erdogan,Umut Demirci,Pinar Gursoy,Hakan Harputluoglu,Atakan Demir,Kai-Keen Shiu,Ewan Brown,Paul Ross,Elizabeth Smyth,Ian Chau,Mark Saunders,Gina Vaccaro,Steven McCune,Raymond Wadlow,Gazala Khan,Babar Bashir,Michael Koontz,Ludmila Martin,Ardaman Shergill,Patrick Cobb,Mark Kochenderfer,the LEAP-017 Investigators
DOI: https://doi.org/10.1200/jco.23.02736
IF: 45.3
2024-06-05
Journal of Clinical Oncology
Abstract:PURPOSE Treatment options are limited for patients with previously treated metastatic colorectal cancer (mCRC). In the LEAP-017 study, we evaluate whether lenvatinib in combination with pembrolizumab improves outcomes compared with standard of care (SOC) in previously treated mismatch repair proficient or not microsatellite instability high (pMMR or not MSI-H) mCRC. METHODS In this international, multicenter, randomized, controlled, open-label, phase III study, eligible patients age 18 years and older with unresectable, pMMR or not MSI-H mCRC, that had progressed on or after, or could not tolerate, standard treatment, were randomly assigned 1:1 to lenvatinib 20 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks or investigator's choice of regorafenib or trifluridine/tipiracil (SOC). Randomization was stratified by presence or absence of liver metastases. The primary end point was overall survival (OS). LEAP-017 is registered at ClinicalTrials.gov ( NCT04776148 ), and has completed recruitment. RESULTS Between April 8, 2021, and December 21, 2021, 480 patients were randomly assigned to lenvatinib plus pembrolizumab (n = 241) or SOC (n = 239). At final analysis (median follow-up of 18.6 months [IQR, 3.9]), median OS with lenvatinib plus pembrolizumab versus SOC was 9.8 versus 9.3 months (hazard ratio [HR], 0.83 [95% CI, 0.68 to 1.02]; P = .0379; prespecified threshold P = .0214). Grade ≥3 treatment-related adverse events occurred in 58.4% (lenvatinib plus pembrolizumab) versus 42.1% (SOC) of patients. Two participants died due to treatment-related adverse events, both in the lenvatinib plus pembrolizumab arm. CONCLUSION In patients with pMMR or not MSI-H mCRC that had progressed on previous therapy, there was no statistically significant improvement in OS after lenvatinib plus pembrolizumab treatment versus SOC. No new safety signals were observed.
oncology